AI drug platform for undruggables
Business Model:
Revenue: $0
Employees: 11-50
Address:
City: Copenhagen
State: Hovedstaden
Zip:
Country: Denmark
Dianox is a founder-led biotechnology startup with a computational drug discovery platform for targeting undruggable proteins. Big opportunity as 85% of proteins are undruggable with small molecules and unreachable by antibodies. Our platform consists of the world&s;s largest nucleic acid database and a proprietary Deep Learning model that enables us to generate novel nucleic acids for efficient delivery to previously undruggable proteins. It can be used to design drugs for oncology, neurology, etc. We believe good health is the most important aspect of life. Our company is dedicated to building better therapeutics and diagnostics to help people in their health journey. We are always on the lookout for passionate partners in the health space. If you are excited about the potential of our work, please reach out via [email protected].
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 2/2020 | Grant | 2 | - |
European regional development fund (ERDF) Innovation Fund Denmark European regional development fund (ERDF) Innovation Fund Denmark |
7/2022 | Non Equity Assistance | 2 | - |
GSK NEXT R/GA Ventures GSK NEXT R/GA Ventures |
7/2022 | Non Equity Assistance | 2 | - |
GSK NEXT R/GA Ventures GSK NEXT R/GA Ventures |
2/2020 | Grant | 2 | - |
European regional development fund (ERDF) Innovation Fund Denmark European regional development fund (ERDF) Innovation Fund Denmark |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|